RNS Number : 7781Q
Kromek Group PLC
02 March 2021

**2 March 2021**

**Kromek Group plc**
("Kromek" or the "Company")

**PDMR Dealings**

As set out in the Circular dated 12 February 2021 and the announcement made on 1 March 2021 (RNS: 7457Q), certain of the Directors of the Company indicated their intention to participate in the Transaction. Following completion of the Transaction and on Admission, their interests will be as follows:

| *Name* | *Role* | *Number of Ordinary Shares held* | *Number of Ordinary Shares held as a percentage of the Existing Ordinary Shares* | *Value of Placing and Open Offer intended to be subscribed for (£)* | *Number of Placing Shares to be applied for in the Firm Placing* | *Number of Directors' Subscription Shares to be subscribed for in the Directors' Subscription* | *Number of Open Offer Shares subscribed for* | *Number of Ordinary Shares held following the Firm Placing, Directors' Subscription and Open Offer* | *Percentage of Ordinary Shares held following the Firm Placing, Directors' Subscription and Open Offer* |
|---|---|---|---|---|---|---|---|---|---|
| Rakesh Sharma | Chairman | 178,454 | 0.05 | 19,988 | - | 133,250 | - | 311,704 | 0.07 |
| Arnab Basu | CEO | 2,972,000 | 0.86 | 2,513 | - | 16,750 | - | 2,988,750 | 0.69 |
| Paul Farquhar | CFO | - | - | 9,975 | 66,500[1] | - | - | 66,500 | 0.02 |
| Lawrence Kinet | Non-Executive Director | 300,000 | 0.09 | 7,500 | - | 50,000 | - | 350,000 | 0.08 |
| Christopher Wilks | Non-Executive Director | 175,000 | 0.05 | 442 | - | - | 2,941 | 177,941 | 0.04 |

[1] Includes subscriptions by family, as defined in the AIM rules for Companies.

Capitalised terms used, but not defined, in this announcement have the same meaning as set out in the Circular.

**For further information, please contact:**

**Kromek Group plc**
Arnab Basu, CEO +44 (0)1740 626 060
Paul Farquhar, CFO

**Cenkos Securities plc (Nominated Adviser and Broker)**
Max Hartley/Camilla Hume (NOMAD) +44 (0)20 7397 8900

Julian Morse (Sales)

**Luther Pendragon (PR)**
Harry Chathli/Claire Norbury/Joe Quinlan +44 (0)20 7618 9100

**The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:**

| | | |
|---|---|---|
| **1** | **Details of the person discharging managerial responsibilities / person closely associated** | |
| a) | Name | 1. Rakesh Sharma<br>2. Arnab Basu<br>3. Paul Farquhar<br>4. Caroline Farquhar<br>5. Lawrence Kinet<br>6. Christopher Wilks |
| **2** | **Reason for the notification** | |
| a) | Position/status | 1. Rakesh Sharma (Non-executive Chairman)<br>2. Arnab Basu (CEO)<br>3. Paul Farquhar (CFO)<br>4. Caroline Farquhar (PCA to CFO)<br>5. Lawrence Kinet (Non-executive Director)<br>6. Christopher Wilks (Non-executive Director) |
| b) | Initial notification /Amendment | Initial Notification |
| **3** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor** | |
| a) | Name | Kromek Group plc |
| b) | LEI | 213800VLHYXGHEX5VQ48 |
| **4** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted** | |
| a) | Description of the financial instrument, | Ordinary Shares of 1p each in the capital of the Company |

| | | |
|---|---|---|
| | type of instrument | |
| b) | Identification code | GB00BD7V5D43 |
| c) | Nature of the transaction | Purchase of ordinary shares |
| d) | Price and volumes | All shares were purchased at 15p per share as follows:<br>1. Rakesh Sharma - 133,250 shares<br>2. Arnab Basu - 16,750 shares<br>3. Paul Farquhar - 33,250 shares<br>4. Caroline Farquhar - 33,250 shares<br>5. Lawrence Kinet - 50,000 shares<br>6. Christopher Wilks - 2,941 shares |
| e) | Aggregated information<br>- Aggregated volume<br>- Price | See above |
| f) | Date of the transaction | 2 March 2021 |
| g) | Place of the transaction | London Stock Exchange |

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHJBMMTMTTMTAB